Retractable Technologies has announced a 7% workforce reduction as it pivots away from Chinese manufacturing amid rising trade tensions. The Texas-based syringe and needle manufacturer cited the potential impact of Trump-era tariffs—recently paused for 90 days—as a key driver behind the move.
Strategic Shift to U.S. Manufacturing
- The company aims to increase domestic production and decrease reliance on Chinese imports.
- The decision comes as tariffs on Chinese goods remain uncertain, despite a temporary suspension for some regions.
Industry group AdvaMed welcomed the pause, but China remains excluded, leaving medtech firms exposed to future disruptions.
Retractable’s move signals a broader industry trend toward supply chain reshoring and tariff-proof resilience in the evolving global trade landscape.
Follow MEDWIRE.AI for more on medtech manufacturing and trade policy shifts.
